Vanda Pharmaceuticals Inc (VNDA) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Rising ...

GuruFocus News

Thu, May 8, 2025, 12:28 AM 4 min read

• Total Revenue: $50 cardinal for Q1 2025, a 5% summation from $47.5 cardinal successful Q1 2024.

• Fanapt Net Product Sales: $23.5 cardinal for Q1 2025, a 14% summation from $20.6 cardinal successful Q1 2024.

• HETLIOZ Net Product Sales: $20.9 cardinal for Q1 2025, a 4% summation from $20.1 cardinal successful Q1 2024.

• PONVORY Net Product Sales: $5.6 cardinal for Q1 2025, an 18% alteration from $6.8 cardinal successful Q1 2024.

• Net Loss: $29.5 cardinal for Q1 2025, compared to a nett nonaccomplishment of $4.1 cardinal successful Q1 2024.

• Operating Expenses: $91.1 cardinal for Q1 2025, compared to $56.7 cardinal successful Q1 2024.

• Cash and Equivalents: $340.9 cardinal arsenic of March 30, 2025, a alteration of $33.7 cardinal from December 31, 2024.

• Fanapt Total Prescriptions: Increased by astir 14% successful Q1 2025 compared to Q1 2024.

• Fanapt New Patient Starts: Increased astir threefold successful Q1 2025 compared to Q1 2024.

• Warning! GuruFocus has detected 4 Warning Signs with VNDA.

Release Date: May 07, 2025

For the implicit transcript of the net call, delight notation to the full net telephone transcript.

• Fanapt's commercialized maturation has accelerated, with play prescriptions surpassing 2,000, marking it arsenic 1 of the fastest-growing atypical antipsychotics.

• Vanda Pharmaceuticals Inc (NASDAQ:VNDA) has expanded its psychiatry income unit to astir 300 representatives, enhancing its marketplace reach.

• The institution has a affluent pipeline with caller caller cause exertion filings for tradipitant and Bysanti, indicating beardown R&D productivity.

• HETLIOZ continues to clasp the largest information of marketplace stock contempt facing generic contention for implicit 2 years.

• Vanda Pharmaceuticals Inc (NASDAQ:VNDA) has entered into an exclusive planetary licence statement for Imsidolimab, establishing a promising anti-inflammatory franchise.

• Vanda Pharmaceuticals Inc (NASDAQ:VNDA) recorded a nett nonaccomplishment of $29.5 cardinal for the archetypal 4th of 2025, importantly higher than the $4.1 cardinal nonaccomplishment successful the archetypal 4th of 2024.

• PONVORY nett merchandise income decreased by 18% compared to the archetypal 4th of 2024, chiefly owed to a alteration successful volume.

• Operating expenses accrued by $34.4 million, driven by higher R&D and SG&A expenses, impacting profitability.

• HETLIOZ nett merchandise income whitethorn diminution successful aboriginal periods owed to continued generic contention and inventory stocking variability.

• The institution faces imaginable gross variability owed to the Medicare Benefit redesign, which could negatively interaction gross-to-net for Medicare payer segments.

Q: What benignant of placebo-adjusted alteration connected [Maddrey's oregon Hamdi] would you privation to spot for a competitory illustration for milsaperidone oregon Bysanti? A: Mihael Polymeropoulos, CEO, stated that they person not pre-specified the margin. The superior endpoint volition beryllium the alteration from baseline arsenic compared to placebo, acknowledging the variability successful large slump studies.